Recombinant Mouse Anti-TrkA Antibody (MNAC13) (CAT#: PABX-182)

Guo, Zhiliang, Yuanyuan Liu, and Min Cheng. "Resveratrol protects bupivacaine-induced neuro-apoptosis in dorsal root ganglion neurons via activation on tropomyosin receptor kinase A." Biomedicine & Pharmacotherapy 103 (2018): 1545-1551. https://doi.org/10.1016/j.biopha.2018.04.155

This research investigated whether resveratrol (RSV) could protect against bupivacaine (BUP)-induced neurotoxicity in spinal cord dorsal root ganglia (DRG). Using cultured mouse DRG neurons, the study demonstrated that RSV exhibited significant protective effects against BUP-induced neuro-apoptosis in a concentration-dependent manner. The researchers found that while RSV did not alter TrkA/B/C gene or protein expression, it significantly upregulated phosphorylated TrkA. When a functional TrkA blocking antibody (MNAC13) was applied, the protective effects of RSV were reversed, demonstrating that RSV's neuroprotective activity against anesthesia-induced apoptosis operates primarily through activation of the TrkA signaling pathway.
Creative Biolabs provided the functional TrkA blocking antibody MNAC13 used in this study, which was crucial for confirming the mechanism of RSV-mediated neuroprotection. By applying MNAC13 to inhibit TrkA signaling, the researchers were able to demonstrate that phospho-TrkA upregulation was essential for RSV's protective effect, as blocking this pathway reversed the anti-apoptotic benefits. This antibody tool enabled the researchers to conclusively identify TrkA activation as the underlying mechanism through which RSV protects against anesthesia-induced neurotoxicity, providing valuable insights for potential therapeutic interventions to prevent neural damage during spinal anesthesia.